Results 211 to 220 of about 4,014,458 (336)
Abstract Aims Prednisone is a widely used glucocorticoid in the treatment of lupus, although its dosing is often determined empirically. Prednisolone, the active metabolite of prednisone, is found in its free form in the serum. The goal of this study was to develop a population pharmacokinetic model in patients with systemic lupus erythematosus (SLE ...
Naïm Bouazza+26 more
wiley +1 more source
Inpatient Psychiatric Unit Availability Within US Short-Term, Acute-Care Hospitals, 2011-2023.
Lindenfeld Z+4 more
europepmc +1 more source
Civil Monetary Penalties from Violations of the Emergency Medical Treatment and Labor Act for Patients Arriving or Leaving with Law Enforcement. [PDF]
Ahmed S+11 more
europepmc +1 more source
Expert insight into the education of healthcare professionals on medication adherence
Abstract Aims Medication non‐adherence is a global health problem affecting patients with numerous medical conditions. Training healthcare professionals (HCPs) on managing the challenging issue of medication non‐adherence requires an evidence‐based approach.
Fatima Rezae+3 more
wiley +1 more source
Mortality in national psychiatric hospitals in Sudan: a fifteen-year review of hospital deaths. [PDF]
Hussein M Osman A+4 more
europepmc +1 more source
Human health benefit and burden of the schizophrenia health care pathway in Belgium : paliperidone palmitate long-acting injections [PDF]
De Smedt, Delphine+4 more
core +1 more source
Aims Several methods exist to identify hospital admissions related to adverse drug events (ADEs). Clinical adjudication by healthcare professionals is the gold standard but is labour‐intensive. Spontaneous reporting and routinely collected healthcare data using a set of International Classification of Diseases (ICD) codes often underestimate the ...
Zuzana Juhásová+2 more
wiley +1 more source
Evolving trends in psychiatric emergency services in Southern China: a seven-year retrospective analysis. [PDF]
Zhang C+5 more
europepmc +1 more source
Aims We sought to characterize adverse events and deaths associated with the use of psychoactive substances in children and adolescents. Methods Two French Addictovigilance databases were analysed: spontaneous reports and deaths over the period 2016–2021, in subjects aged 10–<18 years. An unsupervised classification was implemented on consumption data (
Hélène Peyrière+13 more
wiley +1 more source